

Congress of the United States
House of Representatives

COMMITTEE ON OVERSIGHT AND ACCOUNTABILITY

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074
MINORITY (202) 225-5051

<https://oversight.house.gov>

April 14, 2023

Susan T. Mayne, Ph.D.
Director, Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration
5001 Campus Dr.
College Park, MD 20740

Dear Dr. Mayne:

The Committee on Oversight and Accountability Subcommittee on Health Care and Financial Services is continuing to investigate the U.S. Food and Drug Administration's (FDA) response to the 2022 infant formula shortage. Based on our investigation, the Subcommittee believes you have valuable information that will assist the Subcommittee's understanding of the FDA's response to this crisis.

I invited you to appear before the Subcommittee. To accommodate you and the FDA, the Subcommittee provided multiple dates for you to appear. You allegedly are not available on those dates. The only dates the FDA provided conflict with pre-existing Committee business and Congressional events. Therefore, in light of the foregoing and your impending retirement, we request that you make yourself available for a transcribed interview on May 3, 2023.

To confirm your appearance, please contact Subcommittee on Health Care and Financial Services staff at (202) 225-5074 by April 17, 2023. The Committee on Oversight and Accountability is the principal oversight committee of the U.S. House of Representatives and has broad authority to investigate "any matter" at "any time" under House Rule X.

Sincerely,



Lisa McClain

Chairwoman

Subcommittee on Health Care and Financial Services

cc: The Honorable Katie Porter, Ranking Member
Subcommittee on Health Care and Financial Services